- |||||||||| CBT-1 (tetrandrine) / CBA Pharma
Preclinical, Journal: Tetrandrine Enhances Radiosensitization in Human Hepatocellular Carcinoma Cell Lines. (Pubmed Central) - Apr 7, 2019
Moreover, when PA28γ was downregulated, apoptosis and cell cycle distribution were also altered; however, the effects were weaker in p53-mutant cells. Therefore, we propose that tetrandrine-mediated apoptosis induction and G arrest attenuation are at least partly mediated by PA28γ.
- |||||||||| CBT-1 (tetrandrine) / CBA Pharma
Preclinical, Journal: Therapeutic effect of dihydroartemisinin on pulmonary fibrosis in rats with dust (Pubmed Central) - Apr 2, 2019
Dihydroartemisinin can down-regulate the level of inflammatory cytokines in rat lung tissue. It is possible to inhibit pulmonary fibrosis by intervening in the TGF-β1/Smad 2/3 signaling pathway, but the therapeutic effect between DHA and tetrandrine is not significantly different in a short time.
- |||||||||| CBT-1 (tetrandrine) / CBA Pharma
Enrollment open, Combination therapy, Metastases: CBT-1 (clinicaltrials.gov) - Apr 6, 2018
P1, N=46, Recruiting,
It is possible to inhibit pulmonary fibrosis by intervening in the TGF-β1/Smad 2/3 signaling pathway, but the therapeutic effect between DHA and tetrandrine is not significantly different in a short time. Not yet recruiting --> Recruiting
- |||||||||| CBT-1 (tetrandrine) / CBA Pharma
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: CBT-1 (clinicaltrials.gov) - Jun 29, 2017
P1, N=46, Not yet recruiting,
Not yet recruiting --> Recruiting Initiation date: Jan 2017 --> Sep 2017 | Trial primary completion date: Dec 2019 --> Sep 2020
- |||||||||| CBT-1 (tetrandrine) / CBA Pharma
Enrollment change, Trial withdrawal, Combination therapy, Metastases: CBT-1 (clinicaltrials.gov) - Jun 20, 2017
P1, N=0, Withdrawn,
Initiation date: Jan 2017 --> Sep 2017 | Trial primary completion date: Dec 2019 --> Sep 2020 N=46 --> 0 | Suspended --> Withdrawn
- |||||||||| CBT-1 (tetrandrine) / CBA Pharma
Trial suspension, Combination therapy, Metastases: CBT-1 (clinicaltrials.gov) - Jun 9, 2017
P1, N=46, Suspended,
N=46 --> 0 | Suspended --> Withdrawn Not yet recruiting --> Suspended
- |||||||||| CBT-1 (tetrandrine) / CBA Pharma
New P1 trial, Combination therapy, Metastases: CBT-1 (clinicaltrials.gov) - Dec 27, 2016
P1, N=46, Not yet recruiting,
|
